Full text is available at the source.
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Guidelines for Using SGLT2 Inhibitors and GLP-1 Receptor Agonists to Treat Kidney Disease in Diabetes
AI simplified
Abstract
Sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) are recommended for heart and kidney protection in diabetes management.
- Diabetic kidney disease is linked with increased risks of kidney failure and cardiovascular mortality.
- SGLT2i and GLP-1 RA have been shown to prevent cardiovascular events and kidney failure.
- Clinical trials have shifted diabetes treatment toward prioritizing heart and kidney protection.
- A decision-making tool is proposed to assist clinicians in evaluating the appropriateness of SGLT2i and GLP-1 RA for patients at high risk.
- The effectiveness of SGLT2i and GLP-1 RA varies across different risk categories for cardiovascular and kidney outcomes.
AI simplified